{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:08:30Z","timestamp":1760854110407,"version":"3.37.3"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/100009408","name":"Brain Canada","doi-asserted-by":"publisher","award":["2015-2017"],"award-info":[{"award-number":["2015-2017"]}],"id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009017","name":"ALS Canada","doi-asserted-by":"publisher","award":["2015-2017"],"award-info":[{"award-number":["2015-2017"]}],"id":[{"id":"10.13039\/100009017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["17996"],"award-info":[{"award-number":["17996"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000240","name":"New Brunswick Innovation Foundation","doi-asserted-by":"publisher","award":["RIF2015-014"],"award-info":[{"award-number":["RIF2015-014"]}],"id":[{"id":"10.13039\/501100000240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,1,17]]},"abstract":"<jats:sec>\n<jats:title>Background::<\/jats:title>\n<jats:p>The current therapeutic options available to patients diagnosed with Amyotrophic\nLateral Sclerosis (ALS) are limited and edaravone is a compound that has gained significant\ninterest for its therapeutic potential in this condition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives: :<\/jats:title>\n<jats:p>The current work was thus undertaken to synthesize and characterize a series of edaravone\nanalogues.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A total of 17 analogues were synthesized and characterized for their antioxidant properties,\nradical scavenging potential and copper-chelating capabilities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Radical scavenging and copper-chelating properties were notably observed for edaravone.\nAnalogues bearing hydrogen in position 1 and a phenyl at position 3 and a phenyl in both positions of\npyrazol-5 (4H)-one displayed substantial radical scavenging, antioxidants and copper-chelating properties.\nHigh accessibility of electronegative groups combined with higher electronegativity and partial\ncharge of the carbonyl moiety in edaravone might explain the observed difference in the activity of\nedaravone relative to the closely related analogues 6 and 7 bearing hydrogen at position 1 and a phenyl\nat position 3 (6) and a phenyl in both positions (7).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Overall, this study reveals a subset of edaravone analogues with interesting properties.\nFurther investigation of these compounds is foreseen in relevant models of oxidative stress-associated\ndiseases in order to assess their therapeutic potential in such conditions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527318666191114092007","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T08:30:39Z","timestamp":1573720239000},"page":"779-790","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties"],"prefix":"10.2174","volume":"18","author":[{"given":"Alexandre","family":"LeBlanc","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Universit\u00e9 de Moncton, Moncton, New Brunswick, NB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslava","family":"Cuperlovic-Culf","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Jr.","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Universit\u00e9 de Moncton, Moncton, New Brunswick, NB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-8012","authenticated-orcid":true,"given":"Mohamed","family":"Touaibia","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Universit\u00e9 de Moncton, Moncton, New Brunswick, NB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/tx700210j","volume":"21","author":"Sayre L.M.","year":"2008","unstructured":"Sayre L.M.; Perry G.; Smith M.A.; Oxidative stress and neurotoxicity. Chem Res Toxicol 2008,21(1),172-188","journal-title":"Chem Res Toxicol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1021\/jm400970m","volume":"57","author":"Rosini M.","year":"2014","unstructured":"Rosini M.; Simoni E.; Milelli A.; Minarini A.; Melchiorre C.; Oxidative stress in Alzheimer\u2019s disease: Are we connecting the dots? J Med Chem 2014,57(7),2821-2831","journal-title":"J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/10715762.2013.857018","volume":"48","author":"Turunc Bayrakdar E.","year":"2014","unstructured":"Turunc Bayrakdar E.; Uyanikgil Y.; Kanit L.; Koylu E.; Yalcin A.; Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A\u03b2(1-42)-induced rat model of Alzheimer\u2019s disease. Free Radic Res 2014,48(2),146-158","journal-title":"Free Radic Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1046\/j.1471-4159.1998.71041616.x","volume":"71","author":"Fay D.S.","year":"1998","unstructured":"Fay D.S.; Fluet A.; Johnson C.J.; Link C.D.; \n                        In vivo aggregation of beta-amyloid peptide variants. J Neurochem 1998,71(4),1616-1625","journal-title":"J Neurochem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1021\/tx960130e","volume":"10","author":"Butterfield D.A.","year":"1997","unstructured":"Butterfield D.A.; \u03b2-Amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer\u2019s disease. Chem Res Toxicol 1997,10(5),495-506","journal-title":"Chem Res Toxicol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.91.8.3270","volume":"91","author":"Hensley K.","year":"1994","unstructured":"Hensley K.; Carney J.M.; Mattson M.P.; A model for \u03b2-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994,91(8),3270-3274","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1871527317666180425122557","volume":"17","author":"Yaribeygi H.","year":"2018","unstructured":"Yaribeygi H.; Panahi Y.; Javadi B.; Sahebkar A.; The underlying role of oxidative stress in neurodegeneration: A mechanistic review. CNS Neurol Disord Drug Targets 2018,17(3),207-215","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11154-013-9271-7","volume":"15","author":"Matsuda M.","year":"2014","unstructured":"Matsuda M.; Shimomura I.; Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord 2014,15(1),1-10","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1179\/1351000213Y.0000000069","volume":"19","author":"Eren E.","year":"2014","unstructured":"Eren E.; Ellidag H.Y.; Cekin Y.; Ayoglu R.U.; Sekercioglu A.O.; Y\u0131lmaz N.; Heart valve disease: The role of calcidiol deficiency, elevated parathyroid hormone levels and oxidative stress in mitral and aortic valve insufficiency. Redox Rep 2014,19(1),34-39","journal-title":"Redox Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(96)90866-1","volume":"347","author":"Stephens N.G.","year":"1996","unstructured":"Stephens N.G.; Parsons A.; Schofield P.M.; Kelly F.; Cheeseman K.; Mitchinson M.J.; Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996,347(9004),781-786","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1161\/01.CIR.90.3.1154","volume":"90","author":"Street D.A.","year":"1994","unstructured":"Street D.A.; Comstock G.W.; Salkeld R.M.; Sch\u00fcep W.; Klag M.J.; Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation 1994,90(3),1154-1161","journal-title":"Circulation"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/01.CIR.86.3.803","volume":"86","author":"Salonen J.T.","year":"1992","unstructured":"Salonen J.T.; Nyyss\u00f6nen K.; Korpela H.; Tuomilehto J.; Sepp\u00e4nen R.; Salonen R.; High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992,86(3),803-811","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3892\/ol.2014.1863","volume":"7","author":"Wang J.","year":"2014","unstructured":"Wang J.; Li J.Z.; Lu A.X.; Zhang K.F.; Li B.J.; Anticancer effect of salidroside on A549 lung cancer cells through inhibition of oxidative stress and phospho-p38 expression. Oncol Lett 2014,7(4),1159-1164","journal-title":"Oncol Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bcp.2014.04.001","volume":"90","author":"Granados-Principal S.","year":"2014","unstructured":"Granados-Principal S.; El-Azem N.; Pamplona R.; Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem Pharmacol 2014,90(1),25-33","journal-title":"Biochem Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.2174\/09298673113203690142","volume":"20","author":"Tekiner-Gulbas B.","year":"2013","unstructured":"Tekiner-Gulbas B.; Westwell A.D.; Suzen S.; Oxidative stress in carcinogenesis: New synthetic compounds with dual effects upon free radicals and cancer. Curr Med Chem 2013,20(36),4451-4459","journal-title":"Curr Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ijc.2910560315","volume":"56","author":"Knekt P.","year":"1994","unstructured":"Knekt P.; Reunanen A.; Takkunen H.; Aromaa A.; Heli\u00f6vaara M.; Hakulinen T.; Body iron stores and risk of cancer. Int J Cancer 1994,56(3),379-382","journal-title":"Int J Cancer"},{"key":"ref=17","first-page":"1597","volume":"268","author":"Watanabe T.","year":"1994","unstructured":"Watanabe T.; Yuki S.; Egawa M.; Nishi H.; Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994,268(3),1597-1604","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.STR.0000056171.55342.FF","volume":"34","author":"Yoneda Y.","year":"2003","unstructured":"Yoneda Y.; Uehara T.; Yamasaki H.; Kita Y.; Tabuchi M.; Mori E.; Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke 2003,34(3),718-724","journal-title":"Stroke"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","volume":"344","author":"Rowland L.P.","year":"2001","unstructured":"Rowland L.P.; Shneider N.A.; Amyotrophic lateral sclerosis. N Engl J Med 2001,344(22),1688-1700","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1212\/WNL.50.1.62","volume":"50","author":"Gurney M.E.","year":"1998","unstructured":"Gurney M.E.; Fleck T.J.; Himes C.S.; Hall E.D.; Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998,50(1),62-66","journal-title":"Neurology"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001447","author":"Miller R.G.","year":"2002","unstructured":"Miller R.G.; Mitchell J.D.; Lyon M.; Moore D.H.; Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev 2002(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2174\/1871527317666180720162029","volume":"17","author":"Chico L.","year":"2018","unstructured":"Chico L.; Ienco E.C.; Bisordi C.; Amyotrophic lateral sclerosis and oxidative stress: A double-blind therapeutic trial after curcumin supplementation. CNS Neurol Disord Drug Targets 2018,17(10),767-779","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2174\/1871527318666190409103831","volume":"18","author":"Li L.","year":"2019","unstructured":"Li L.; Liu J.; She H.; Targeting macrophage for the treatment of amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2019,18(5),366-371","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=24","first-page":"945","volume":"16","author":"Caballero-Villarraso J.","year":"2017","unstructured":"Caballero-Villarraso J.; Galvan A.; Escribano B.M.; Tunez I.; Interrelationships among gut microbiota and host: paradigms, role in neurodegenerative diseases and future prospects. CNS Neurol Disord Drug Targets 2017,16(8),945-964","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=25","first-page":"1597","volume":"268","author":"Watanabe T.","year":"1994","unstructured":"Watanabe T.; Yuki S.; Egawa M.; Nishi H.; Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994,268(3),1597-1604","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.expneurol.2008.07.017","volume":"213","author":"Ito H.","year":"2008","unstructured":"Ito H.; Wate R.; Zhang J.; Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008,213(2),448-455","journal-title":"Exp Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.bmcl.2014.01.045","volume":"24","author":"Kamogawa E.","year":"2014","unstructured":"Kamogawa E.; Sueishi Y.; A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox. Bioorg Med Chem Lett 2014,24(5),1376-1379","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1016\/j.bmcl.2006.09.005","volume":"16","author":"Nakagawa H.","year":"2006","unstructured":"Nakagawa H.; Ohyama R.; Kimata A.; Suzuki T.; Miyata N.; Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base. Bioorg Med Chem Lett 2006,16(23),5939-5942","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/jp110400t","volume":"115","author":"P\u00e9rez-Gonz\u00e1lez A.","year":"2011","unstructured":"P\u00e9rez-Gonz\u00e1lez A.; Galano A.; OH radical scavenging activity of Edaravone: mechanism and kinetics. J Phys Chem B 2011,115(5),1306-1314","journal-title":"J Phys Chem B"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13510002.1996.11747069","volume":"2","author":"Yamamoto Y.","year":"1996","unstructured":"Yamamoto Y.; Kuwahara T.; Watanabe K.; Watanabe K.; Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 1996,2(5),333-338","journal-title":"Redox Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1021\/jm8007008","volume":"52","author":"Chegaev K.","year":"2009","unstructured":"Chegaev K.; Cena C.; Giorgis M.; Edaravone derivatives containing NO-donor functions. J Med Chem 2009,52(2),574-578","journal-title":"J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.4103\/1673-5374.141808","volume":"9","author":"Zhang T.","year":"2014","unstructured":"Zhang T.; Li Z.; Dong J.; Nan F.; Li T.; Yu Q.; Edaravone promotes functional recovery after mechanical peripheral nerve injury. Neural Regen Res 2014,9(18),1709-1715","journal-title":"Neural Regen Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neuro.2013.07.007","volume":"38","author":"Zhou S.","year":"2013","unstructured":"Zhou S.; Yu G.; Chi L.; Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. Neurotoxicology 2013,38,136-145","journal-title":"Neurotoxicology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.expneurol.2008.05.011","volume":"213","author":"Tokuda E.","year":"2008","unstructured":"Tokuda E.; Ono S.; Ishige K.; Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol 2008,213(1),122-128","journal-title":"Exp Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/cbdd.12874","volume":"89","author":"Doiron J.A.","year":"2017","unstructured":"Doiron J.A.; Leblanc L.M.; H\u00e9bert M.J.; Structure-activity relationship of caffeic acid phenethyl ester analogs as new 5-lipoxygenase inhibitors. Chem Biol Drug Des 2017,89(4),514-528","journal-title":"Chem Biol Drug Des"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1021\/jf9911242","volume":"48","author":"Li\u00e9geois C.","year":"2000","unstructured":"Li\u00e9geois C.; Lermusieau G.; Collin S.; Measuring antioxidant efficiency of wort, malt, and hops against the 2,2\u2032-azobis(2-amidinopropane) dihydrochloride-induced oxidation of an aqueous dispersion of linoleic acid. J Agric Food Chem 2000,48(4),1129-1134","journal-title":"J Agric Food Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1021\/acs.jmedchem.6b00636","volume":"59","author":"Li X.","year":"2016","unstructured":"Li X.; Wang H.; Lu Z.; Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J Med Chem 2016,59(18),8326-8344","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017,7,42717","journal-title":"Sci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.bmcl.2003.07.016","volume":"13","author":"Wang L.F.","year":"2003","unstructured":"Wang L.F.; Zhang H.Y.; A theoretical investigation on DPPH radical-scavenging mechanism of edaravone. Bioorg Med Chem Lett 2003,13(21),3789-3792","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"019","DOI":"10.17352\/ijpsdr.000007","volume":"2","author":"Wan X","year":"2016","unstructured":"Wan X; Luo MX; Jie C; Wu T; Yu GY; Edaravone protects against vascular oxidative damage induced by AAPH in chick embryo. Int J Pharm Sci Dev Res 2016,2(1),019-22","journal-title":"Int J Pharm Sci Dev Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nature09018","volume":"465","author":"Banci L.","year":"2010","unstructured":"Banci L.; Bertini I.; Ciofi-Baffoni S.; Kozyreva T.; Zovo K.; Palumaa P.; Affinity gradients drive copper to cellular destinations. Nature 2010,465(7298),645-648","journal-title":"Nature"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tox.2006.09.011","volume":"229","author":"Tokuda E.","year":"2007","unstructured":"Tokuda E.; Ono S.; Ishige K.; Naganuma A.; Ito Y.; Suzuki T.; Metallothionein proteins expression, copper and zinc concentrations, and lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis. Toxicology 2007,229(1-2),33-41","journal-title":"Toxicology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1021\/ci034148o","volume":"43","author":"Gilson M.K.","year":"2003","unstructured":"Gilson M.K.; Gilson H.S.R.; Potter M.J.; Fast assignment of accurate partial atomic charges: an electronegativity equalization method that accounts for alternate resonance forms. J Chem Inf Comput Sci 2003,43(6),1982-1997","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"Veber D.F.","year":"2002","unstructured":"Veber D.F.; Johnson S.R.; Cheng H.Y.; Smith B.R.; Ward K.W.; Kopple K.D.; Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002,45(12),2615-2623","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1021\/jm1013693","volume":"54","author":"Meanwell N.A.","year":"2011","unstructured":"Meanwell N.A.; Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011,54(8),2529-2591","journal-title":"J Med Chem"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T08:59:31Z","timestamp":1582102771000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176668\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,1,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527318666191114092007","relation":{},"ISSN":["1871-5273"],"issn-type":[{"type":"print","value":"1871-5273"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}